Two Sigma Advisers
TCON

Two Sigma Advisers’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Two Sigma Advisers’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-515
Closed -$19.5K – 2722
2023
Q1 		$19.5K Sell
515
-2,145
-81% -$70.3K ﹤0.01% 2520
2022
Q4 		$79.3K Sell
2,660
-2,375
-47% -$71.8K ﹤0.01% 2322
2022
Q3 		$168K Sell
5,035
-2,990
-37% -$114K ﹤0.01% 2236
2022
Q2 		$321K Sell
8,025
-2,425
-23% -$93.9K ﹤0.01% 2093
2022
Q1 		$550K Sell
10,450
-6,150
-37% -$309K ﹤0.01% 1936
2021
Q4 		$920K Sell
16,600
-1,790
-10% -$114K ﹤0.01% 1603
2021
Q3 		$1.42M Buy
18,390
+4,185
+29% +$354K ﹤0.01% 1435
2021
Q2 		$1.84M Sell
14,205
-1,165
-8% -$161K ﹤0.01% 1328
2021
Q1 		$2.53M Buy
15,370
+2,685
+21% +$517K 0.01% 1155
2020
Q4 		$2.97M Buy
+12,685
New +$1.77M 0.01% 1067
2020
Q3 		– Sell
-2,770
Closed -$109K – 2678
2020
Q2 		$109K Buy
2,770
+2,120
+326% +$83.9K ﹤0.01% 2346
2020
Q1 		$22K Buy
+650
New +$37.8K ﹤0.01% 2411

Other funds holding TCON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's TCON Position: Q2 2023 in Review

Two Sigma Advisers sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2023, closing a stake of 515 shares — an estimated $19.5K sold.

Two Sigma Advisers first reported a position in TCON in Q1 2020 and held it in 12 quarters. The position peaked at $2.97M in Q4 2020. 27 funds tracked by Wall St. Rank hold TCON as of Q2 2023.

  • Two Sigma Advisers reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 515 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $19.5K.
  • Two Sigma Advisers first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
  • Two Sigma Advisers's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $2.97M in Q4 2020.
  • 27 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.